Shinya Tanaka

This study identifies microvascular pathology and endothelial proteotoxicity as key features of Progressive Supranuclear Palsy through neuropathological and single-nucleus RNA-sequencing analysis.

This study experimentally infects horseshoe bats with SARS-CoV-2, showing low-level persistent viral replication without disease, and identifies host mechanisms that enable viral coexistence.

The paper identifies CXCR4 as a meningioma stem cell marker induced by hydrogel reprogramming and demonstrates its potential for diagnostic and therapeutic applications.

The paper identifies a protein-folding stress-associated microglial state in PSP brains and shows it is distinct from DAM, driven by ER stress.

This study identifies the non-spike R204P mutation in the SARS-CoV-2 Omicron XEC variant as a driver of increased inflammation and pathogenicity through NF-κB activation.

This study identifies TIMELESS as a critical regulator of metastasis-initiating cell survival and reawakening in bone, with a metabolic inhibitor showing promise for therapeutic intervention.

This study investigates the evolutionary changes from BA.2.86 to JN.1, showing that non-spike protein mutations compensate for reduced spike protein replication, enhancing viral fitness.

The paper investigates the virological features of the SARS-CoV-2 EG.5.1 variant, finding its fitness and antiviral sensitivity comparable to XBB.1.5, with structural differences in spike proteins.

This study introduces AkaBLI, a method using Akaluc bioluminescence to track SARS-CoV-2 infection in vivo with higher sensitivity than NanoLuc, showing its utility in monitoring viral dynamics and vaccine efficacy.

This study investigates the virological characteristics of the SARS-CoV-2 BA.2.86 variant, finding it has higher reproduction number than EG.5.1 but lower pathogenicity and replication capacity compared to BA.2.

This study investigates the virological properties of the SARS-CoV-2 HK.3 variant, a FLip variant with substitutions S:L455F and S:F456L, to assess its growth advantage.